Depth bar: Due-diligence dossier for Band A outreach. Estimates marked [~]; directory facts [dir]; unverified claims [!]. Never invent bill numbers, court outcomes, or emails.

1. Company overview & snapshot

HAB Pharmaceuticals and Research Limited is a private WHO-GMP formulations company (antibiotics, NSAIDs, cardiovascular and expanding specialty) with manufacturing in Mumbai and Dehradun/Selaqui. In March 2026 HAB completed a strategic slump-sale merger with Signature Phytochemical Industries (Uttarakhand oral formulations, founded ~2016). Consolidated turnover after intercompany adjustment is cited around ₹600 crore, with public ambition of ₹2,500–3,000 crore by 2030 (ETPharma, Pharmabiz, BW Healthcare, PNI). Two new plants — sterile (semaglutide/PFS/injectables/lyophilised) and automated closed-loop OSD — targeted for commercial production by August 2026. Directors Saurabh Agarwal and Urvee Garg speak publicly on integration. Plant Head Vikas Arya (LinkedIn, Dehradun since Apr 2025); CTO Shyam Saini welcomed Feb 2026 at Dehradun factory.

1.1 Legal identity & corporate structure

Private limited; Mumbai Peninsula Business Park HQ listings (Tower A / A301 variants). CIN cited on aggregators as U99999MH1997PLC105340 [dir — confirm MCA]. Signature assets now inside HAB via slump sale — confirm which UPCL accounts and GSTINs still exist separately during integration. Selaqui Plot No. 10 Pharma City (lead report) is the working plant address.

1.2 What they make & where money comes from

Formulations across antibiotics, CV, NSAIDs; export to LATAM/Central Asia/SEA/Africa with MOH audits (Uganda, Tanzania, Iraq cited). Push into complex/specialty and GLP-1 related sterile capacity. Contract manufacturing plus own brands.

1.3 Plants, addresses & footprint

Pilot: Plot No. 10, Pharma City, Selaqui, Dehradun 248197 [lead]. Confirm vs Signature unit addresses that may still appear on google maps. Mumbai plant is secondary for this campaign. Sterile/OSD new plants — confirm co-location before scoping.

1.4 Leadership & CRM map

Vikas Arya — Plant Head Dehradun (primary). Saurabh Agarwal — Director / growth (economic). Shyam Saini — CTO Dehradun factory (technical ally). Ganesh Poojari — CFO (lists). Decision: plant head sponsors 90-day → director if multi-site EMS politics arise.

1.5 Recent news (24 months) & timing for Stamped

Merger Mar 2026; sterile/OSD commissioning target Aug 2026; ET Make in India SME Dehradun presence. Timing risk: post-merger vendor freezes 6–12 months — counter with scoped kill criteria and plant-local fee. Timing opportunity: new loads need baseline now.

2. Energy profile

DISCOM / supply (name early): UPCL (Uttarakhand Power Corporation Ltd) supplies Selaqui Pharma City HT industrial consumers. Name UPCL early in all call prep.

2.1 Bill band, tariff & demand

₹600 Cr formulations with HVAC-heavy cleanrooms commonly clear ₹30–80 lakh/month per major Dehradun site [~]. Post-merger bills may be fragmented — discovery must map every UPCL account. New sterile will step-change MD mid-pilot if timing overlaps — plan normalisation.

2.2 Generation, fuel & renewables

Ask DG capacity, boiler/TFH, purified water generation power, and any solar. Sterile plants often keep high UPS/HVAC base loads.

2.3 EnMS, PAT, ISO, BRSR

WHO-GMP and upcoming EU GMP ambition; ISO 50001 not confirmed. Environmental plantation posts exist (soft CSR).

2.4 Likely ₹ leak categories (hypothesis)

(1) Fragmented post-merger UPCL accounts hiding true campus MD; (2) HVAC hold between batches; (3) compressor staging; (4) WFI/PW continuous; (5) commissioning dumps during sterile validation; (6) DG vs grid poor decisions.

3. Operations, equipment & digital stack

3.1 Process flow & critical loads

Dispensing → granulation/compression or liquid/sterile fill → coating/packing → QC → warehouse. Critical: HVAC AHUs, chillers, compressors, purified water, sterilisation, dust collection.

3.2 Shifts, seasonality, production pattern

Campaign batch pharma; validation campaigns spike overtime. Normalise by batch count / pack units.

3.3 Automation, metering, SCADA/EMS/DCS

Closed-loop OSD claim implies advanced automation. Path A: BMS/EMS export + UPCL bills.

3.4 Capex / tech projects affecting energy

Sterile + OSD Aug 2026 — central to timing.

4. Stamped Energy fit analysis

4.1 ICP scorecard

UK Selaqui — pass. Pharma — pass. Revenue Band A — pass. Bill unknown. Private — good accessibility if plant head engaged.

4.2 Fit score rationale

Fit 8/10: merger + commissioning wedge; integration freeze is the main deduction.

4.3 Wedge (parser-critical)

The strongest wedge is: post-Signature-merger utility attribution at Selaqui — whether HVAC, compressors and WFI still read as one UPCL story or fragmented accounts — plus a 90-day baseline before sterile/OSD commercial loads rewrite demand, with every avoidable ₹ assigned to an owner and verified with evidence.

4.4 Objections & competitors

“Integration freeze” → 90-day kill, one feeder. “We are building EMS into new plants” → Stamped sits above, bill-verifies. “Talk Mumbai” → Vikas owns plant utilities.

4.5 Pilot design

Selaqui existing Pharma City HT account first; optional second phase after sterile COD. Success: one owned HVAC/MD action + invoice link.

5. Before you reach out

5.1 Discovery checklist

• List all UPCL accounts post-merger.
• ₹ lakh/month each; sanctioned MD.
• Sterile/OSD COD date vs pilot window.
• Vikas + engineering + QA constraints on HVAC setback.
• Two bills + batch calendar.
• ISO/BMS vendor names.

5.2 Do not lead with

• Do not lead with dashboards, AI buzzwords, generic ESG, or a promised percentage reduction presented as fact.
• Do not lead with semaglutide hype as Stamped expertise.
• Do not treat Signature as still a separate sales account without checking invoice.
• Do not promise EU GMP outcomes.

5.3 Opening hooks (email / call / WhatsApp)

“After Signature, do Selaqui utility bills still read as one plant — and who owns the MD when sterile validation starts?“

6. Risks, flags, controversies & sources

6.1 Integrity / controversy / regulatory (search explicitly)

• Merger execution risk: Integration distractions (not a legal controversy).
• Regulatory: Expanding into sterile/GLP-1 space increases FDA/EU inspection intensity — may freeze OT changes; keep read-only pitch.
• Litigation/PCB/labour: No HAB-specific NGT closure, scam allegation, or major labour dispute found in July 2026 search sample.
• Search: HAB Pharmaceuticals / Signature Phytochemicals + lawsuit, PCB, FDA warning, labour, scam 2024–2026.

6.2 Data quality flags

• Exact Selaqui plot confirm on visit.
• Consolidated ₹600 Cr is management/press figure.
• Emails inferred.

6.3 Sources consulted

• ETPharma / Pharmabiz / BW Healthcare / PNI merger articles May–2026.
• habpharma.in ; LinkedIn company + Vikas Arya + Saurabh Agarwal.
• Lead report UK gap verticals July 2026.

Extended call-prep narrative (Stamped field use)

B1. First 20 minutes of discovery

Open with process respect, not software. Confirm legal entity on the invoice, DISCOM name, and who owns the largest feeder MD event in the last 90 days. Ask for two invoices and one production calendar export before any platform demo. If the champion cannot produce bills within a week, treat the opportunity as stalled — Bill Verification Program without invoices is theatre. Record whether Path A (historian/meter export) or Path B (CSV) is realistic given OT policy. Confirm the economic buyer who can approve a Rs 2–5 lakh [~] fixed 90-day fee without a full ERP tender.

B2. Prescription card discipline

Every recommendation must name: event, owner, due date, expected rupee line on the DISCOM invoice, operational constraint, and evidence of execution. Cards without owners are deleted. Cap weekly cards at five so plant teams are not flooded. Prefer MD sequencing and idle-hold cuts before exotic tariff products. Never propose changing validated recipe, membrane current, sterile pressure, or Tempcore quench parameters. If quality or safety forbids a schedule change, mark the lever as blocked and move on — credibility beats aggressive savings claims.

B3. Verifying savings without gaming

A lower bill alone is not success if tonnes, pairs, or batches fell. Normalise against a production proxy agreed in week 1. Document holidays, forced outages, new-line commissioning, captive/solar settlement changes, and weather-sensitive HVAC. Keep a decision ledger shared with the plant: recommendation, owner, status, expected vs observed invoice delta. Present kill or expand at day 90 with the same ledger — this is how Stamped differs from audit PDFs that never close.

B4. Competitive and incumbent handling

If the site has EMS/SCADA/BMS, OEM analytics, ISO consultants, or solar EPCs, congratulate the spend and ask what residual bill lines still surprise them monthly. Position Stamped as the closure layer: rupee assignments and invoice reconciliation. Refuse head-to-head dashboard bake-offs. If Gujarat, Panipat, or Noida corporate IT appears, keep plant electrical as the proof owner and let corporate rubber-stamp after a verified bill line — not before.

B5. Geographic and cluster logistics

Batch 3 spans Mandi Gobindgarh, Paonta/Derabassi/Rajpura, Ghaziabad/Muzaffarnagar, and Kanpur–Unnao. Plan field days by corridor. Carry printed one-pagers: Fit score, DISCOM hypothesis, strongest wedge sentence, and two discovery questions. After each visit, update extras field intel — especially corrected phones, electrical names, and whether the bill cleared Rs 30 lakh/month.

B6. Messaging hygiene for this batch

Owner-operated steel/leather accounts tolerate Hindi-friendly WhatsApp and short calls. Listed pharma/chemical accounts prefer email plus LinkedIn with technical depth. Never open with controversies (GST/Excise history, EuGMP observations, rating actions) — those are internal briefings only. Always name DISCOM early in research-backed prep sheets so call-prep UI can render correctly.

6.4 Evidence discipline and next research actions

This dossier separates three evidence classes. Verified public facts come from company websites, CRISIL/ICRA ratings, BSE/NSE filings, press releases, and named LinkedIn profiles. Directional operating hypotheses follow from disclosed process (press lines, dairy utilities, fryers, forging, pharma HVAC/BFS) and are not claims about a specific machine failure. Commercial estimates—especially monthly electricity bills—remain estimates until the site shares a current HT invoice and production context.

Practical sequence after first contact: (1) verify legal entity and invoice ownership; (2) collect two DISCOM invoices with tariff, demand and PF lines; (3) identify the top three load events with the electrical/utility owner; (4) map production constraints that cannot move; (5) agree the smallest controllable boundary for a 90-day trial. Calculate demand, energy, reactive/PF and tariff components separately. Normalise against strokes, litres, batches or tonnes. Record baseline dates, shutdowns, commissioning, fuel/captive changes and weather-sensitive HVAC. Keep a decision ledger: recommendation, owner, due date, constraint, expected ₹ line, evidence, invoice result.

Security: confirm historian export, meter CSV or supervised read-only access; retention; IT/OT roles. No proposal implies changing PLC logic, recipes, interlocks, setpoints or operator authority. Treat adverse information proportionately — a negative search is not a clearance; a regional NGT matter is not automatic guilt for an unrelated site.

7. Extended plant diligence notes (Batch 4 depth addendum)

7.1 Post-merger bill archaeology

The Signature Phytochemicals slump sale creates accounting consolidation without automatic electrical consolidation. Discovery question one: how many UPCL consumer numbers exist across Plot 10 Pharma City and any Signature sheds? If Vikas Arya cannot answer, the pilot’s first two weeks are bill archaeology — valuable even before prescriptions.

7.2 Commissioning collision

Sterile and OSD plants targeting August 2026 commercial production will inject validation loads (SIP, sterilisation, HVAC qualification) that destroy baselines. Either finish a 90-day proof before COD, or redefine success as avoidable MD per validation protocol with QA in the room. Never promise HVAC setbacks that violate Grade segregation.

7.3 Private-company speed vs Mumbai HQ

HAB’s Mumbai Peninsula HQ and Dehradun plant can disagree. Saurabh Agarwal’s public growth narrative is the economic story; Vikas is the operating story. If Mumbai procurement freezes vendors during integration, offer a plant-signed 90-day with kill criteria under a small opex budget — or park and revisit post-COD. Document the freeze as a timing flag, not a disqualification forever.

7.4 GLP-1 / sterile distraction

Semaglutide and PFS headlines will attract vendors pitching compliance software. Explicitly separate Stamped from QMS/MES: utilities bill layer only. That honesty wins plant engineering trust.

7.5 CTO Shyam Saini as ally

February 2026 CTO appointment at Dehradun factory is a gift if he owns digital/utilities stack. Invite him to the technical scoping call early so Stamped is not perceived as shadow IT.

7.6 Export audit calendar

Uganda/Tanzania/Iraq-style MOH audits and EU GMP chase create blackout weeks for change. Schedule prescription trials around those windows.

8. Call-prep annex — HAB Selaqui

8.1 Sixty-second plant story (memorise)

HAB merged Signature Phytochemicals in March 2026 into a ~Rs 600 Cr consolidator and is commissioning sterile and automated OSD plants toward August 2026. Selaqui utilities may still be fragmented across UPCL accounts. The sell is post-merger attribution plus baseline before sterile loads rewrite demand.

8.2 Integration freeze playbook

If Vikas says “not now,” ask whether freeze is: (a) systems merge, (b) budget lock, or (c) QA validation blackout. Each has a different revisit date. Log it in CRM.

8.3 Sample discovery questions (extra)

• Count of UPCL consumer numbers?
• Signature shed still energised separately?
• Sterile COD date confidence (red/amber/green)?
• Who owns CAPEX vs OPEX under Rs 5L at plant?
• HVAC BMS vendor?
• Any EU GMP inspection date on calendar?

8.4 Mumbai vs Dehradun meeting choreography

Prefer first call with Vikas alone; second call add Shyam Saini; third include Saurabh only if budget needs director. Flooding the first call with Mumbai BD loses technical thread.

8.5 Prescription themes that survive QA

Stagger compressor banks; reduce corridor HVAC overdrive outside production; fix compressed air leaks; align DG exercise with off-peak; never touch Grade A differentials without QA written ok.

8.6 Competitive vendors likely on site

Cleanroom OEMs, UPS vendors, purified water OEMs — they sell hardware. Position Stamped as bill layer after their assets exist.

9a. Selaqui HAB-specific contingency notes

If merger IT freeze is hard, schedule revisit for September 2026 after sterile/OSD COD noise settles — unless Vikas can approve a one-feeder opex under plant budget. If Signature accounts remain live, include them in discovery even if marketing says “one company now.” If Saurabh pivots call to products/exports, book a second technical slot with Vikas/Shyam.

9. Scenario planning & commercial contingencies

9.1 Three scenario tree

Scenario A — Fast proof: Bill clears the Band A floor, champion shares two invoices in week one, and Path A data export works. Compress discovery, issue first prescription cards by day 14, chase a clear invoice line by day 75.

Scenario B — Slow politics: Champion is interested but corporate or QA freezes vendor onboarding. Keep a monthly nurture with one process-specific insight; do not burn the economic buyer. Re-open after a dated event (COD, ISO audit, season peak).

Scenario C — Bill gate fail: Site is process-fit but HT spend sits under Rs 30 lakh/month. Offer Path B only if volatility or MD pain is extreme; otherwise park with a reminder to revisit after expansion.

9.2 Red-team of the wedge

Ask: could a competent internal electrical team get 60% of the value with a spreadsheet? If yes, Stamped must emphasise continuity, WhatsApp assignment, and DISCOM verification friction they will not sustain manually. Ask: is the wedge dependent on a single charismatic champion? If yes, recruit a deputy owner in week two.

9.3 Documentation pack for MSA later

Keep: invoice redactions, consumer number, sanctioned demand, feeder sketch, champion org chart, data access memo, kill criteria signed in email, weekly prescription log. These become the audit trail when finance asks why software opex exists.

9.4 Ethics and claims discipline

Do not overstate early-deployment percentages as guarantees. Label estimates. Do not invent lawsuits. Do not use Apollo. Do not commit hardware. Do not imply PLC writes. If a press or pharma quality constraint blocks a prescription, document and skip — credibility compounds.

9.5 Local logistics

Plan travel clusters: Greater Noida Ecotech + YEIDA Jewar in one day; Lucknow Gudamba + PTC SMTC in one trip; Selaqui HAB + NATCO in one morning; Haridwar Themis + Roorkee Axa in one SIDCUL/Roorkee loop. Carry printed one-pagers without confidential third-party data.

10. Source critique & residual unknowns (HAB)

Merger articles (ETPharma, Pharmabiz, BW, PNI) agree on March 2026 timing, ~Rs 600 Cr consolidator turnover, and August 2026 sterile/OSD COD ambition, but they are management communications. Residual unknowns: Exact Pharma City plots retained post-Signature, number of UPCL accounts, whether sterile plant is on the same land parcel, and plant opex approval limits. LinkedIn confirms Vikas Arya plant head tenure starting April 2025 — verify he still holds the role before send. Treat 2030 Rs 3,000 Cr target as vision, not near-term bill evidence.

11. Stamped operating principles for this account

Stay plant-first. Prefer one feeder over campus mythology. Prefer WhatsApp-assigned prescriptions over dashboard logins. Prefer DISCOM lines over kWh hero metrics. Prefer kill criteria over indefinite pilots. Prefer truth about unknowns over false precision. Re-validate champion LinkedIn tenure the morning of outreach. Never commit without two bills. Never write to PLCs. Never expand scope mid-pilot because the champion is friendly — expand only after invoice proof.

12. Outreach sequencing memorandum

Week 0: confirm LinkedIn tenure and email pattern offline. Week 1: LinkedIn connect + short email; request two HT bills. Week 2: 20-minute call using cold-call bullets; map DISCOM lines. Week 3: send written 90-day scope with kill criteria and feeder sketch. Week 4-12: if contracted, weekly prescription cards and invoice checkpoints. If no reply after two touches, try secondary champion once, then park with a calendar reminder tied to a plant event (COD, season peak, audit close). Never pile four channels in 48 hours — it reads as spam. Keep WhatsApp for after a warm yes or phone capture. Log every objection in CRM using the objection table in section 4.4 so future agents do not repeat failed angles. When a champion forwards internally, ask who now owns the decision and restart discovery with that person rather than assuming prior context transferred cleanly.